
  
    
      
        Background_NNP
        Mefloquine_NNP (_( Lariam_NNP )_) is_VBZ a_DT prophylactic_JJ antimalarial_NN that_WDT
        is_VBZ also_RB used_VBN for_IN malaria_NN chemotherapy_NN ._. Adverse_JJ central_JJ
        nervous_JJ system_NN (_( CNS_NNP )_) events_NNS have_VBP been_VBN associated_VBN with_IN its_PRP$
        use_NN ._. Severe_NNP CNS_NNP events_NNS requiring_VBG hospitalization_NN occur_VB in_IN
        1_CD :_: 10_CD ,_, 000_CD and_CC 1_CD :_: 200_CD -_: 1200_CD patients_NNS taking_VBG mefloquine_NN for_IN
        chemoprophylaxis_NNS and_CC treatment_NN ,_, respectively_RB [_NN 1_CD ]_NN ._. Milder_NNP
        CNS_NNP events_NNS (_( e_SYM ._. g_SYM ._. dizziness_NN ,_, headache_NN and_CC insomnia_NN )_) are_VBP a_DT
        more_RBR frequent_JJ occurrence_NN ,_, occurring_VBG in_IN up_IN to_TO 25_CD %_NN of_IN those_DT
        receiving_VBG chemoprophylactic_JJ doses_NNS and_CC 90_CD %_NN of_IN patients_NNS
        receiving_VBG therapeutic_JJ doses_NNS [_NN 1_CD ]_NN ._. Higher_JJR blood_NN levels_NNS of_IN
        mefloquine_NN are_VBP reached_VBN under_IN prophylactic_JJ as_IN compared_VBN to_TO
        therapeutic_JJ regimens_NNS [_NN 1_CD 2_CD ]_NN ._. The_DT relative_JJ incidence_NN of_IN
        adverse_JJ effects_NNS is_VBZ ,_, therefore_RB ,_, probably_RB dose-related_JJ ,_,
        although_IN the_DT concomitant_NN effect_NN of_IN malaria_NN during_IN treatment_NN
        cannot_NN be_VB dismissed_VBN ._. It_PRP is_VBZ likely_JJ ,_, then_RB ,_, that_IN the_DT
        neurological_JJ events_NNS associated_VBN with_IN mefloquine_NN have_VBP a_DT
        biochemical_JJ basis_NN ._. In_IN this_DT study_NN ,_, an_DT attempt_NN was_VBD made_VBN to_TO
        deduce_NN a_DT possible_JJ mechanism_NN of_IN action_NN for_IN mefloquine_NN in_IN rat_NN
        neuronal_NN cells_NNS using_VBG Affymetrix_NNP rat_NN toxicology_NN arrays_NNS ._.
        Microarray_NNP analysis_NN offers_VBZ the_DT unique_JJ potential_NN to_TO
        identify_VB unknown_JJ targets_NNS of_IN toxic_JJ agents_NNS ,_, as_IN
        transcriptional_NN responses_NNS of_IN the_DT entire_JJ genome_NN can_MD be_VB
        measured_VBN in_IN parallel_JJ [_NN 3_CD ]_NN ._. Ideally_RB ,_, one_PRP should_MD be_VB able_JJ to_TO
        identify_VB new_JJ targets_NNS quickly_RB ,_, confidently_RB ,_, and_CC without_IN
        recourse_NN to_TO alternative_JJ methods_NNS ._. Appropriate_NNP selection_NN of_IN a_DT
        method_NN for_IN filtering_VBG gene_NN expression_NN data_NNS is_VBZ therefore_RB
        critical_JJ to_TO this_DT process_NN ._. One_CD of_IN the_DT first_JJ definitions_NNS to_TO
        emerge_VB was_VBD the_DT arbitrary_JJ designation_NN of_IN a_DT particular_JJ level_NN
        of_IN -_: usually_RB two-fold_JJ up_RP or_CC down_RB regulation_NN -_: gene_NN
        expression_NN as_IN representing_VBG '_POS significance_NN '_'' [_NN 4_CD 5_CD ]_NN ._. Such_JJ
        arbitrary_JJ definitions_NNS emerged_VBD from_IN the_DT observation_NN that_IN
        fold-regulation_JJ of_IN genes_NNS between_IN control_NN cultures_NNS with_IN
        identical_JJ cell_NN populations_NNS seldom_RB varies_VBZ by_IN more_JJR than_IN this_DT
        level_NN (_( discussed_VBN by_IN Ideker_NNP et_CC al_NN ._. [_NN 6_CD ]_NN )_) ._.
        However_RB ,_, arbitrary_JJ designations_NNS cannot_NN be_VB considered_VBN
        '_POS significant_JJ '_POS in_IN the_DT traditional_JJ ,_, statistical_JJ sense_NN unless_IN
        experimental_JJ variance_NN is_VBZ taken_VBN into_IN consideration_NN ._. An_DT
        evolving_VBG method_NN of_IN analysis_NN is_VBZ to_TO define_VB significant_JJ
        changes_NNS in_IN gene_NN expression_NN in_IN terms_NNS of_IN a_DT particular_JJ 
        P_NN -_: value_NN after_IN performing_VBG appropriate_JJ
        statistical_JJ tests_NNS that_WDT take_VBP into_IN account_NN the_DT variability_NN of_IN
        gene_NN expression_NN data_NNS and_CC sample_NN size_NN [_NN 6_CD 7_CD 8_CD 9_CD 10_CD ]_NN ._.
        However_RB ,_, care_NN must_MD be_VB taken_VBN to_TO use_VB appropriate_JJ statistical_JJ
        tests_NNS ,_, 
        P_NN -_: value_NN thresholds_NNS for_IN significance_NN ,_,
        and_CC sufficient_JJ 
        n_NN ,_, otherwise_RB ,_, variance-based_JJ
        methods_NNS ,_, as_IN with_IN less_RBR rigorous_JJ fold-change_JJ approaches_NNS ,_, will_MD
        generate_VB high_JJ error_NN rates_NNS ._. Recent_JJ studies_NNS have_VBP discussed_VBN
        the_DT utility_NN of_IN the_NNP '_POS Z_NNP score_NN '_'' ,_, the_DT parametric_JJ t-test_JJ ,_, and_CC
        the_DT nonparametric_JJ Wilcoxon_NNP rank_NN sum_NN test_NN for_IN expression_NN
        profiling_VBG [_NN 9_CD 10_CD ]_NN ._. However_RB ,_, the_DT effects_NNS of_IN inadequate_JJ
        sample_NN size_NN and_CC 
        P_NN -_: value_NN correction_NN methods_NNS are_VBP only_RB
        beginning_VBG to_TO be_VB addressed_VBN [_NN 11_CD ]_NN ._.
        Due_JJ to_TO restrictions_NNS on_IN the_DT type_NN and_CC availability_NN of_IN
        biological_JJ samples_NNS and_CC the_DT prohibitive_JJ cost_NN of_IN arrays_NNS ,_, many_JJ
        array_NN studies_NNS have_VBP resorted_JJ to_TO the_DT use_NN of_IN extremely_RB low_JJ
        sample_NN sizes_NNS (_( for_IN a_DT recent_JJ example_NN see_VB Lang_NNP et_CC al_NN ._. [_NN 12_CD ]_NN
        )_) ._. This_DT is_VBZ potentially_RB problematic_JJ because_IN the_DT power_NN of_IN
        statistical_JJ tests_NNS decreases_NNS with_IN sample_NN size_NN ._. There_EX is_VBZ also_RB
        the_DT multiplicity_NN problem_NN [_NN 13_CD ]_NN ._. As_IN the_DT number_NN of_IN
        hypotheses_NNS being_VBG tested_VBN increases_NNS so_RB does_VBZ the_DT number_NN of_IN
        type_NN I_PRP errors_NNS (_( false_JJ conclusions_NNS of_IN significance_NN )_) ._. This_DT is_VBZ
        of_IN great_JJ concern_NN in_IN microarray_NN studies_NNS given_VBN the_DT number_NN of_IN
        statistical_JJ comparisons_NNS being_VBG made_VBN (_( i_NNP ._. e_SYM ._. one_CD test_NN per_IN gene_NN
        on_IN an_DT array_NN )_) ._. Therefore_RB ,_, 
        P_NN -_: value_NN correction_NN is_VBZ essential_JJ in_IN
        expression_NN profiling_VBG to_TO control_VB an_DT appropriate_JJ type_NN 1_CD error_NN
        rate_NN ,_, although_IN undue_JJ conservatism_NN may_MD result_VB in_IN the_DT failure_NN
        to_TO detect_VB transcriptional_NN changes_NNS for_IN some_DT genes_NNS that_WDT might_MD
        indeed_RB be_VB verifiable_JJ by_IN other_JJ means_NNS ._. As_IN shown_VBN in_IN this_DT
        study_NN ,_, adoption_NN of_IN an_DT experimental_JJ design_NN that_WDT incorporates_VBZ
        an_DT adequate_JJ sample_NN size_NN and_CC appropriate_JJ selection_NN of_IN a_DT 
        P_NN -_: value_NN filtering_VBG method_NN is_VBZ critical_JJ
        if_IN genes_NNS with_IN altered_VBN transcription_NN are_VBP to_TO be_VB efficiently_RB
        and_CC effectively_RB identified_VBN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Reagents_NNP and_CC media_NNS
          Mefloquine_NNP was_VBD obtained_VBN from_IN Walter_NNP Reed_NNP Army_NNP
          Institute_NNP of_IN Research_NNP chemical_NN repository_NN ._. Dulbecco_NNP 's_POS
          Modified_NNP Eagle_NNP Medium_NNP (_( DMEM_NNP )_) ,_,
          hypoxanthine-aminopterin-thymidine_JJ (_( HAT_NNP )_) medium_NN
          supplement_NN ,_, foetal_NN calf_NN serum_NN (_( FCS_NNP )_) and_CC gentamycin_NN were_VBD
          purchased_VBN from_IN Gibco_NNP BRL_NNP (_( Rockville_NNP ,_, Maryland_NNP )_) ._. RNA-STAT_NNP
          was_VBD obtained_VBN from_IN Tel-_NNP Test_NNP (_( Friendswood_NNP ,_, Texas_NNP )_) ._.
        
        
          Cell_NNP maintenance_NN
          NG_NNP 108_CD -_: 15_CD (_( mouse_NN neuroblastoma-rat_JJ glioma_NN hybrid_JJ )_) cells_NNS
          were_VBD maintained_VBN in_IN 75_CD -_: cm_NN 2_CD tissue_NN culture_NN flasks_NNS in_IN DMEM_NNP
          supplemented_JJ with_IN HAT_NNP ,_, 10_CD %_NN FCS_NNP and_CC gentamycin_NN (_( 50_CD μg_NN /_NN ml_NN )_) ,_,
          in_IN a_DT humidified_JJ 6_CD ._. 0_CD %_NN CO_NNP 
          2_CD incubator_NN at_IN 37_CD °_NN C_NNP ._. For_IN the_DT
          microarray_NN studies_NNS ,_, 175_CD cm_NN 2_CD tissue_NN culture_NN flasks_NNS were_VBD
          seeded_VBN with_IN 4_CD ._. 6_CD million_CD NG_NNP 108_CD cells_NNS in_IN 49_CD ._. 6_CD ml_NN culture_NN
          medium_NN 24_CD h_NN prior_RB to_TO the_DT experiments_NNS ._. For_IN cytotoxicity_NN
          studies_NNS ,_, 25_CD cm_NN 2_CD tissue_NN culture_NN flasks_NNS were_VBD seeded_VBN with_IN
          0_CD ._. 66_CD million_CD NG_NNP 108_CD cells_NNS in_IN 10_CD ml_NN culture_NN medium_NN 24_CD h_NN
          prior_RB to_TO the_DT experiment_NN ._.
        
        
          Cytotoxicity_NNP of_IN mefloquine_NN in_IN NG_NNP 108_CD and_CC primary_JJ rat_NN
          neuronal_NN cell_NN cultures_NNS
          The_DT cytotoxicity_NN of_IN mefloquine_NN was_VBD assessed_VBN using_VBG 25_CD
          cm_NN 2_CD tissue_NN culture_NN flasks_NNS ._. After_IN overnight_JJ incubation_NN of_IN
          NG_NNP 108_CD cells_NNS ,_, culture_NN media_NNS were_VBD replaced_VBN with_IN fresh_JJ DMEM_NNP
          containing_VBG mefloquine_NN (_( 2_CD ._. 5_LS -_: 40_CD μM_NN )_) or_CC 1_CD %_NN DMSO_NNP (_( control_NN )_) ._.
          After_IN incubation_NN of_IN the_DT flasks_NNS for_IN 2_CD h_NN ,_, the_DT cells_NNS were_VBD
          washed_VBN twice_RB ,_, and_CC then_RB resuspended_JJ ,_, in_IN 5_CD ml_NN phosphate_NN
          buffered_JJ saline_NN ._. Total_JJ numbers_NNS of_IN viable_JJ cells_NNS at_IN each_DT
          mefloquine_NN concentration_NN were_VBD determined_VBN using_VBG trypan_NN
          blue_JJ exclusion_NN as_RB previously_RB described_VBD [_NN 14_CD ]_NN ._. Viability_NNP
          (_( %_NN )_) was_VBD calculated_VBN using_VBG the_DT following_JJ formula_NN :_: Viability_NNP
          (_( %_NN )_) =_SYM #_# viable_JJ cells_NNS in_IN treated_VBN culture_NN /_NN #_# viable_JJ cells_NNS in_IN
          control_NN culture_NN *_NN 100_CD ._. Data_NNP shown_VBN represent_VB the_DT mean_NN (_( %_NN )_)
          viability_NN (_( ±_NN SEM_NNP )_) for_IN three_CD experiments_NNS ._. The_DT cytotoxicity_NN
          of_IN mefloquine_NN to_TO primary_JJ embryonic_JJ rat_NN neurons_NNS was_VBD
          assessed_VBN in_IN 24_CD well_RB tissue_NN culture_NN plates_NNS using_VBG the_DT MTT_NNP
          assay_NN as_RB previously_RB described_VBD [_NN 15_CD ]_NN ._. Data_NNP represent_VB
          mean_VB (_( %_NN )_) viability_NN (_( ±_NN SEM_NNP )_) for_IN eight_CD replicate_VB
          experiments_NNS ._. Fifty_NNP percent_NN inhibitory_NN concentrations_NNS (_( IC_NNP 
          50_CD s_VBZ )_) were_VBD calculated_VBN using_VBG Prism_NNP
          software_NN ._.
        
        
          Design_NNP of_IN microarray_NN experiments_NNS ,_, cell_NN harvesting_NN
          and_CC total_JJ RNA_NNP extraction_NN
          On_IN the_DT day_NN of_IN the_DT experiment_NN ,_, the_DT media_NNS was_VBD removed_VBN
          from_IN the_DT seeded_VBN flasks_NNS and_CC replaced_VBN with_IN 70_CD ml_NN DMEM_NNP
          supplemented_JJ with_IN either_DT 0_CD ._. 25_CD %_NN DMSO_NNP (_( controls_NNS )_) or_CC 10_CD μM_NN
          mefloquine_NN in_IN 0_CD ._. 25_CD %_NN DMSO_NNP (_( treated_VBN )_) ._. The_DT cells_NNS were_VBD
          treated_VBN with_IN mefloquine_NN or_CC DMSO_NNP for_IN 2_CD h_NN ._. This_DT treatment_NN
          regime_NN reduces_VBZ the_DT viability_NN of_IN NG_NNP 108_CD cells_NNS by_IN
          approximately_RB 35_CD %_NN (_( Figure_NN 1_LS )_) ._. After_IN incubation_NN ,_, media_NNS was_VBD
          removed_VBN and_CC replaced_VBN with_IN 15_CD ._. 0_CD ml_NN RNA_NNP STAT_NNP (_( Tel-_NNP Test_NNP ,_,
          Friendswood_NNP Texas_NNP )_) ._. Total_NNP RNA_NNP was_VBD then_RB extracted_VBN
          according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._. Eight_CD pairs_NNS
          of_IN RNA_NNP samples_NNS (_( eight_CD control_NN and_CC eight_CD treated_VBN samples_NNS )_)
          were_VBD collected_VBN on_IN different_JJ occasions_NNS ._.
        
        
          CDNA_NNP synthesis_NN ,_, in_IN vitro_NN transcription_NN and_CC
          fluorescent_NN labeling_VBG ,_, hybridization_NN ,_, staining_VBG and_CC
          scanning_VBG of_IN gene_NN chips_NNS ,_, and_CC assay_NN monitoring_VBG
          Detailed_NNP procedures_NNS for_IN preparation_NN of_IN cDNA_NN and_CC
          fluorescently_RB labeled_VBN cRNA_NN ,_, hybridization_NN ,_, staining_VBG ,_, and_CC
          scanning_VBG of_IN gene_NN chips_NNS and_CC assay_NN monitoring_VBG are_VBP outlined_VBN
          by_IN Vahey_NNP 
          et_CC al_NN ._. [_NN 16_CD ]_NN ._. The_DT platform_NN
          chosen_VBN for_IN global_JJ expression_NN profile_NN was_VBD the_DT Rat_NNP Tox_NNP U_NNP 34_CD
          Array_NNP (_( Affymetrix_NNP ,_, Santa_NNP Clara_NNP ,_, California_NNP )_) ,_, which_WDT
          contains_VBZ probes_NNS for_IN EST_NNP clusters_NNS and_CC genes_NNS linked_VBN to_TO a_DT
          variety_NN of_IN toxic_JJ endpoints_NNS (_( total_NN of_IN 1031_CD probe_NN sets_NNS
          including_VBG controls_NNS )_) ._. RNA_NNP (_( 10_CD μg_NN )_) extracted_VBN from_IN each_DT
          individual_JJ flask_NN was_VBD hybridized_JJ to_TO a_DT single_JJ gene_NN chip_NN
          (_( i_NNP ._. e_SYM ._. a_DT total_NN of_IN 16_CD chips_NNS were_VBD used_VBN )_) ._.
        
        
          Gene_NNP expression_NN data_NNS analysis_NN
          Affymetrix_NNP analysis_NN software_NN (_( version_NN 4_LS )_) was_VBD used_VBN to_TO
          generate_VB average_JJ difference_NN (_( AD_NNP )_) values_NNS for_IN each_DT gene_NN for_IN
          each_DT treatment_NN (_( Affymetrix_NNP ,_, Santa_NNP Clara_NNP ,_, California_NNP )_) ._. AD_NNP
          values_NNS represent_VBP the_DT difference_NN in_IN mean_NN fluorescence_NN
          between_IN positive_NN and_CC mismatch_NN probe_NN cells_NNS for_IN each_DT gene_NN ._.
          All_DT genes_NNS with_IN mean_NN AD_NNP levels_NNS <_NN 100_CD in_IN either_DT
          mefloquine_NN or_CC DMSO-treated_NNP cultures_NNS were_VBD excluded_VBN ._. This_DT
          procedure_NN eliminated_VBN most_JJS of_IN the_DT genes_NNS called_VBD absent_JJ by_IN
          the_DT Affymetrix_NNP software_NN ._. For_IN simplicity_NN ,_, an_DT AD_NNP value_NN is_VBZ
          hereafter_RB referred_VBN to_TO as_IN the_DT expression_NN value_NN of_IN a_DT gene_NN ._.
          The_DT expression_NN values_NNS for_IN each_DT gene_NN chip_NN were_VBD imported_VBN
          directly_RB into_IN Parteck_NNP Pro_FW 2000_CD ._. No_DT additional_JJ data_NN
          normalization_NN or_CC scaling_VBG methods_NNS were_VBD employed_VBN (_( as_IN these_DT
          procedures_NNS were_VBD performed_VBN previously_RB by_IN the_DT Affymetrix_NNP
          software_NN )_) ._. No_DT additional_JJ filtering_VBG of_IN data_NNS was_VBD conducted_VBN
          on_IN the_DT basis_NN of_IN either_DT number_NN of_IN reporting_VBG probe_NN cells_NNS or_CC
          the_DT present_JJ /_NN absent_JJ calls_VBZ generated_VBN by_IN the_DT Affymetrix_NNP
          analysis_NN software_NN ._. Paired_NNP t-tests_JJ (_( two-sided_JJ ,_, df_NN =_SYM 7_CD )_)
          were_VBD performed_VBN to_TO compare_VB the_DT expression_NN levels_NNS of_IN each_DT
          of_IN the_DT remaining_VBG genes_NNS (_( 695_CD of_IN 1031_CD )_) in_IN DMSO_NNP and_CC
          mefloquine-treated_JJ cultures_NNS ._. The_DT genes_NNS were_VBD then_RB rank_NN
          ordered_VBD in_IN terms_NNS of_IN their_PRP$ unadjusted_JJ 
          P_NN -_: values_NNS ._. This_DT general_JJ approach_NN to_TO
          the_DT analysis_NN of_IN Affymetrix_NNP expression_NN data_NNS is_VBZ outlined_VBN in_IN
          Partek_NNP technical_JJ literature_NN ._. Fold-changes_NNP (_( FC_NNP )_) in_IN
          expression_NN were_VBD =_SYM mean_VB mefloquine_NN expression_NN level_NN /_NN mean_NN
          DMSO_NNP expression_NN level_NN ._.
        
        
          Expression_NNP data_NNS generated_VBN for_IN this_DT study_NN is_VBZ
          available_JJ from_IN GEO_NNP (_( Accession_NNP #_# GSE_NNP 39_CD for_IN a_DT summary_NN of_IN the_DT
          experiment_NN and_CC GSM_NNP 1654_CD -_: 1669_CD for_IN individual_JJ
          treatments_NNS )_)
          
            RT-PCR_NNP validation_NN
            PCR_NNP following_VBG reverse_NN transcription_NN was_VBD performed_VBN
            for_IN semi-quantitative_JJ determination_NN of_IN steady-state_JJ
            expression_NN of_IN RNA_NNP for_IN tubulin_NN (_( negative_JJ control_NN )_) and_CC
            six_CD of_IN the_DT eleven_CD lowest_JJS 
            P_NN -_: value_NN ranked_VBD transcripts_NNS (_( see_VB
            RT-PCR_NNP conditions_NNS in_IN Table_NNP 1_LS )_) ._. For_IN each_DT sample_NN ,_, 2_CD μg_NN
            RNA_NNP was_VBD transcribed_JJ in_IN a_DT 20_CD μl_NN reaction_NN using_VBG the_DT
            Invitrogen_NNP SuperScript_NNP First-_NNP Strand_NNP Synthesis_NNP System_NNP
            oligo-_NN (_( dT_NN )_) primer_NN method_NN according_VBG to_TO the_DT
            manufacturer_NN 's_POS instructions_NNS ._. cDNA_NN was_VBD RNase-treated_NNP (_( 
            E_NNP ._. coli_NNS RNAse_NNP H_NNP at_IN 37_CD °_NN C_NNP for_IN 20_CD
            min_NN )_) and_CC diluted_VBN to_TO 400_CD μl_NN in_IN molecular_JJ biology_NN grade_NN
            water_NN prior_RB to_TO PCR_NNP ._. For_IN each_DT gene_NN ,_, 5_CD μl_NN of_IN cDNA_NN was_VBD
            incorporated_VBN into_IN a_DT 25_CD μl_NN PCR_NNP mixture_NN containing_VBG 8_CD ._. 8_CD mM_NN
            TrisHCL_NNP ,_, 44_CD mM_NN KCl_NNP ,_, 1_CD ._. 3_CD mM_NN MgCl_NNP 
            2_CD ,_, 0_CD ._. 00088_CD %_NN gelatin_NN ,_, 0_CD ._. 284_CD mM_NN each_DT
            deoxynucleoside_NN triphosphate_NN ,_, 1_CD U_NNP of_IN Taq_NNP DNA_NNP polymerase_NN
            (_( Applied_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) and_CC 1_CD ._. 78_CD μM_NN of_IN
            each_DT primer_NN ._. After_IN an_DT initial_JJ denaturation_NN of_IN 94_CD °_NN C_NNP for_IN
            5_CD min_NN ,_, cycles_NNS consisted_VBD of_IN 30_CD sec_NN denaturation_NN at_IN 94_CD °_NN C_NNP ,_,
            30_CD sec_NN of_IN primer_NN annealing_VBG at_IN a_DT gene_NN specific_JJ annealing_VBG
            temperature_NN and_CC 60_CD sec_NN of_IN primer_NN extension_NN at_IN 72_CD °_NN C_NNP ,_,
            followed_VBN by_IN a_DT final_JJ elongation_NN step_NN of_IN 72_CD °_NN C_NNP for_IN 5_CD min_NN ._.
            Cycle_NNP numbers_NNS were_VBD chosen_VBN such_JJ that_DT amplification_NN was_VBD
            in_IN the_DT linear_JJ range_NN of_IN detection_NN ._. PCR_NNP products_NNS (_( 20_CD μl_NN )_)
            were_VBD electrophoresed_JJ on_IN ethidium_NN bromide-stained_JJ 1_CD ._. 2_CD %_NN
            agarose_NN gels_NNS ,_, revealed_VBN by_IN UV_NNP illumination_NN and_CC analyzed_VBD
            densitometrically_RB ._. Gene_NNP specific_JJ primer_NN sequences_NNS ,_,
            cycle_NN times_NNS and_CC annealing_VBG temperatures_NNS are_VBP outlined_VBN in_IN
            Table_NNP 1_CD ._. For_IN each_DT transcript_NN ,_, raw_JJ densitometry_NN data_NNS was_VBD
            subjected_VBN to_TO paired_VBN t-testing_JJ (_( two-sided_JJ ,_, df_NN =_SYM 7_CD )_) to_TO
            determine_VB whether_IN differences_NNS in_IN expression_NN existed_VBD in_IN
            mefloquine_NN and_CC DMSO-treated_NNP cultures_NNS (_( 
            P_NN <_NN 0_CD ._. 05_CD )_) ._.
          
          
            Designation_NNP of_IN a_DT list_NN of_IN genes_NNS with_IN altered_VBN
            expression_NN
            The_DT mefloquine_NN data_NN set_VBN was_VBD used_VBN to_TO compare_VB several_JJ 
            P_NN -_: value_NN correction_NN and_CC gene_NN
            expression_NN filtering_VBG methods_NNS ._. The_DT methods_NNS were_VBD compared_VBN
            in_IN terms_NNS of_IN their_PRP$ ability_NN (_( or_CC failure_NN )_) to_TO detect_VB genes_NNS
            defined_VBN as_IN having_VBG (_( truly_RB )_) altered_VBN expression_NN ._. Genes_NNP
            with_IN altered_VBN changes_NNS in_IN expression_NN were_VBD those_DT with_IN an_DT
            array_NN 
            P_NN <_NN 0_CD ._. 003_CD ._. This_DT threshold_NN was_VBD
            selected_VBN because_IN of_IN the_DT good_JJ correlation_NN of_IN microarray_NN
            and_CC RT-PCR_NNP 
            P_NN -_: values_NNS and_CC because_IN it_PRP
            represents_VBZ the_DT highest_JJS unadjusted_JJ 
            P_NN -_: Value_NNP for_IN which_WDT an_DT associated_VBN
            mefloquine-induced_JJ expression_NN change_NN was_VBD confirmed_VBN by_IN
            RT-PCR_NNP ._.
          
          
            Descriptions_NNP of_IN different_JJ gene_NN expression_NN
            filtering_VBG methods_NNS
            Genes_NNP were_VBD filtered_VBN on_IN the_DT basis_NN of_IN their_PRP$ unadjusted_JJ
            
            P_NN -_: values_NNS according_VBG to_TO several_JJ
            different_JJ methods_NNS :_: (_( i_NNP )_) The_DT normal_JJ 
            P_NN <_NN 0_CD ._. 05_CD threshold_NN (_( i_NNP ._. e_SYM ._. 
            P_NN <_NN 0_CD ._. 05_CD for_IN significance_NN )_) ,_,
            (_( ii_NN )_) the_DT modified_VBN Bonferroni_NNP 's_POS step-down_JJ procedure_NN of_IN
            Holm_NNP or_CC (_( iii_NN )_) the_DT Holm-_NNP Bonferroni_NNP procedure_NN applied_VBN in_IN
            reverse_NN with_IN initial_JJ 
            P_NN -_: values_NNS of_IN 0_CD ._. 05_CD or_CC 0_CD ._. 01_CD ._.
            Applying_VBG the_DT Holm_NNP step-down_JJ procedure_NN [_NN 13_CD ]_NN ,_, the_DT 
            P_NN -_: value_NN threshold_NN for_IN
            significance_NN for_IN each_DT genes_NNS is_VBZ determined_VBN on_IN the_DT basis_NN
            of_IN its_PRP$ rank_NN according_VBG to_TO the_DT following_JJ formula_NN :_: 
            P_NN =_SYM 0_CD ._. 05_CD /_NN (_( total_JJ number_NN of_IN t-tests_JJ
            or_CC genes_NNS in_IN array_NN +_NN 1_CD -_: gene_NN rank_NN )_) ._. Therefore_RB ,_, the_DT gene_NN
            ranked_VBD 1_CD (_( i_NNP ._. e_SYM ._. having_VBG the_DT lowest_JJS 
            P_NN -_: value_NN )_) in_IN an_DT expression_NN set_VBN
            for_IN which_WDT 695_CD statistical_JJ tests_NNS are_VBP to_TO be_VB conducted_VBN ,_,
            the_DT threshold_NN 
            P_NN -_: value_NN is_VBZ 0_CD ._. 05_CD /_NN 695_CD ._. For_IN the_DT
            lowest_JJS ranked_VBN gene_NN (_( i_NNP ._. e_SYM ._. with_IN the_DT highest_JJS 
            P_NN -_: value_NN )_) the_DT threshold_NN is_VBZ
            0_CD ._. 05_CD /_NN 1_CD ._. This_DT method_NN was_VBD also_RB applied_VBN in_IN reverse_NN ,_,
            utilizing_VBG starting_VBG 
            P_NN -_: values_NNS of_IN 0_CD ._. 05_CD and_CC 0_CD ._. 01_CD ,_,
            according_VBG to_TO the_DT following_JJ formula_NN :_: 
            P_NN =_SYM (_( 0_CD ._. 05_CD or_CC 0_CD ._. 01_CD )_) /_NN gene_NN rank_NN ._.
            This_DT approach_NN is_VBZ hereafter_RB referred_VBN to_TO as_IN the_DT reverse_NN
            Holm_NNP procedure_NN ._. For_IN comparison_NN ,_, the_DT expression_NN data_NN
            were_VBD also_RB filtered_VBN using_VBG an_DT ad_NN hoc_FW fold-change_JJ method_NN ._.
            For_IN the_DT fold-change_JJ method_NN ,_, the_DT expression_NN ratios_NNS were_VBD
            calculated_VBN for_IN each_DT gene_NN and_CC a_DT two-fold_JJ change_NN was_VBD used_VBN
            as_IN the_DT criterion_NN for_IN significance_NN ._.
          
          
            Power_NN analysis_NN using_VBG mefloquine_NN data_NNS set_VBN
            In_IN general_JJ ,_, when_WRB using_VBG statistical_JJ tests_NNS (_( in_IN this_DT
            case_NN a_DT paired_VBN t-test_JJ )_) ,_, the_DT required_JJ sample_NN size_NN to_TO
            detect_VB a_DT particular_JJ change_NN (_( e_SYM ._. g_SYM ._. treatment_NN versus_CC
            control_NN )_) depends_VBZ on_IN the_DT magnitude_NN of_IN the_DT difference_NN ,_,
            variability_NN of_IN the_DT data_NNS ,_, the_DT required_JJ statistical_JJ power_NN
            and_CC the_DT acceptable_JJ type_NN 1_CD error_NN ._. The_DT mefloquine_NN data_NN
            set_VBN was_VBD used_VBN to_TO assess_VB the_DT power_NN and_CC implications_NNS of_IN
            sample_NN size_NN in_IN terms_NNS of_IN the_DT minimum_JJ detectable_JJ average_JJ
            fold-change_JJ in_IN expression_NN of_IN the_DT six_CD genes_NNS defined_VBN as_IN
            being_VBG truly_RB upregulated_JJ by_IN the_DT drug_NN ._. First_LS ,_, a_DT publicly_RB
            available_JJ power_NN /_NN sample_NN size_NN calculator_NN (_( [_NN 17_CD ]_NN ,_,
            available_JJ at_IN http_NN :_: /_NN /_NN www_NN ._. mc_NN ._. vanderbilt_NN ._. edu_NN /_NN prevmed_JJ /_NN ps_NNS )_)
            was_VBD used_VBN to_TO determine_VB the_DT power_NN of_IN the_DT paired_VBN test_NN
            (_( two-sided_JJ ,_, df_NN =_SYM 7_CD )_) ._. Then_RB ,_, based_VBN on_IN this_DT level_NN of_IN power_NN
            and_CC the_DT same_JJ critical_JJ values_NNS ,_, absolute_JJ change_NN in_IN
            expression_NN was_VBD calculated_VBN at_IN different_JJ sample_NN sizes_NNS ._.
            The_DT critical_JJ values_NNS for_IN the_DT calculations_NNS were_VBD as_IN
            follows_VBZ ._. The_DT detectable_JJ difference_NN (_( δ_NN )_) was_VBD the_DT
            absolute_JJ ,_, average_JJ changes_NNS in_IN the_DT expression_NN values_NNS of_IN
            the_DT control_NN group_NN ._. The_DT standard_JJ deviation_NN (_( σ_NN )_) was_VBD the_DT
            square_JJ root_NN of_IN the_DT average_JJ variance_NN of_IN differences_NNS in_IN
            expression_NN of_IN the_DT six_CD genes_NNS in_IN individual_JJ pairs_NNS of_IN DMSO_NNP
            and_CC mefloquine-treated_JJ cultures_NNS ._. The_DT type_NN 1_CD error_NN
            (_( two-sided_JJ )_) was_VBD set_VBN at_IN α_NN =_SYM 0_CD ._. 003_CD ,_, which_WDT corresponded_VBD to_TO
            the_DT maximum_NN 
            P_NN -_: value_NN for_IN which_WDT expression_NN
            changes_NNS were_VBD confirmed_VBN by_IN RT-PCR_NNP ._. Absolute_JJ changes_NNS in_IN
            expression_NN at_IN different_JJ sample_NN sizes_NNS are_VBP presented_VBN as_IN
            minimum_JJ detectable_JJ fold-changes_JJ in_IN expression_NN using_VBG the_DT
            following_JJ formula_NN :_: Minimum_NNP detectable_JJ fold-change_JJ =_SYM
            (_( average_JJ expression_NN value_NN of_IN the_DT six_CD upregulated_JJ genes_NNS
            in_IN control_NN cultures_NNS +_NN size_NN of_IN the_DT detectable_JJ
            difference_NN )_) /_NN average_JJ expression_NN value_NN of_IN the_DT six_CD
            upregulated_JJ genes_NNS in_IN control_NN cultures_NNS ._.
          
        
      
      
        Results_NNS
        NG_NNP 108_CD and_CC primary_JJ embryonic_JJ rat_NN neuronal_NN cells_NNS were_VBD
        similarly_RB susceptible_JJ to_TO mefloquine_NN ._. The_DT IC_NNP 
        50_CD s_VBZ of_IN the_DT drug_NN against_IN NG_NNP 108_CD cells_NNS and_CC
        primary_JJ neurons_NNS were_VBD 12_CD and_CC 6_CD ._. 6_CD μM_NN respectively_RB and_CC the_DT
        overall_JJ shapes_NNS of_IN the_DT dose_NN response_NN curves_NNS were_VBD similar_JJ
        (_( Figure_NN 1_LS )_) ._.
        The_DT eleven_CD genes_NNS with_IN the_DT lowest_JJS (_( array_NN )_) 
        P_NN -_: values_NNS are_VBP presented_VBN in_IN Table_NNP 2_CD ._.
        The_DT upregulation_NN by_IN mefloquine_NN of_IN transcripts_NNS encoding_VBG the_DT
        transcription_NN factors_NNS cJun_NN and_CC IkappaB_NNP (_( IkB_NNP )_) and_CC the_DT ER_NNP
        stress_NN protein_NN GADD_NNP 153_CD were_VBD confirmed_VBN by_IN RT-PCR_NNP (_( Table_NNP 2_CD ,_,
        Figure_NN 2_LS )_) ._. All_DT the_DT genes_NNS listed_VBN in_IN Table_NNP 2_CD had_VBD 
        P_NN -_: values_NNS for_IN the_DT microarray_NN
        expression_NN data_NNS substantially_RB less_JJR than_IN 0_CD ._. 05_CD ._. However_RB ,_,
        expression_NN changes_NNS were_VBD only_RB confirmed_VBN for_IN those_DT genes_NNS with_IN
        array_NN 
        P_NN -_: values_NNS <_NN 0_CD ._. 003_CD ._. Also_RB ,_, there_EX was_VBD
        a_DT good_JJ correlation_NN between_IN 
        P_NN -_: values_NNS for_IN the_DT microarray_NN and_CC
        RT-PCR_NNP expression_NN data_NNS (_( r_LS =_SYM 0_CD ._. 97_CD ._. 
        P_NN <_NN 0_CD ._. 002_CD ,_, Figure_NN 3_LS )_) ._. Therefore_RB ,_,
        the_DT seven_CD genes_NNS with_IN array_NN 
        P_NN -_: values_NNS <_NN 0_CD ._. 003_CD were_VBD considered_VBN
        to_TO have_VB expression_NN truly_RB altered_VBN by_IN mefloquine_NN (_( Table_NNP
        2_LS )_) ._.
        The_DT fold-change_JJ and_CC 
        P_NN -_: value_NN filtering_VBG methods_NNS were_VBD
        compared_VBN in_IN terms_NNS of_IN their_PRP$ ability_NN to_TO detect_VB (_( not_RB detect_VB )_)
        genes_NNS differentially_RB modulated_JJ by_IN mefloquine_NN (_( Table_NNP 3_LS )_) ._. The_DT
        fold-change_JJ and_CC 
        P_NN <_NN 0_CD ._. 05_CD filtering_VBG methods_NNS
        detected_VBD all_DT seven_CD differentially_RB expressed_VBD genes_NNS ,_, but_CC also_RB
        identified_VBN many_JJ other_JJ genes_NNS which_WDT ,_, given_VBN their_PRP$ relatively_RB
        high_JJ unadjusted_JJ 
        P_NN -_: values_NNS ,_, are_VBP unlikely_JJ to_TO be_VB
        differentially_RB expressed_VBN (_( i_NNP ._. e_SYM ._. are_VBP probably_RB false_JJ
        positives_NNS )_) ._. The_DT Holm-_NNP Bonferroni_NNP procedure_NN failed_VBD to_TO detect_VB
        any_DT differentially_RB expressed_VBN genes_NNS ._. Other_JJ conservative_JJ
        filtering_VBG methods_NNS described_VBD in_IN the_DT literature_NN [_NN 13_CD ]_NN
        performed_VBN similarly_RB poorly_RB (_( e_SYM ._. g_SYM ._. the_DT Sidak_NNP and_CC Hochberg_NNP
        procedures_NNS )_) ._. The_DT reverse_NN Holm_NNP procedures_NNS detected_VBD more_RBR
        significant_JJ genes_NNS than_IN the_DT Holm-_NNP Bonferroni_NNP method_NN and_CC
        generated_VBN fewer_RBR false_JJ positive_JJ results_NNS than_IN the_DT 
        P_NN <_NN 0_CD ._. 05_CD method_NN ._. However_RB ,_, the_DT more_RBR
        conservative_JJ reverse_NN Holm_NNP method_NN (_( initial_JJ 
        P_NN <_NN 0_CD ._. 01_CD )_) failed_VBD to_TO identify_VB two_CD
        significant_JJ genes_NNS ._.
        The_DT effect_NN of_IN sample_NN size_NN on_IN the_DT ease_NN of_IN detection_NN of_IN
        mefloquine-induced_JJ transcriptional_NN changes_NNS was_VBD then_RB
        examined_VBN ._. The_DT power_NN of_IN a_DT paired_VBN t-test_JJ capable_JJ of_IN detecting_VBG
        the_DT average_JJ change_NN in_IN expression_NN of_IN the_DT six_CD genes_NNS
        upregulated_JJ by_IN mefloquine_NN was_VBD found_VBN to_TO be_VB 50_CD %_NN ._. The_DT effect_NN
        of_IN sample_NN size_NN on_IN the_DT minimum_JJ fold-change_JJ detectable_JJ using_VBG
        a_DT test_NN of_IN such_JJ power_NN is_VBZ illustrated_VBN in_IN Figure_NN 4_CD ._. The_DT
        minimum_JJ detectable_JJ fold-change_JJ increased_VBN with_IN decreasing_VBG
        sample_NN size_NN ._. Reduction_NNP of_IN total_JJ sample_NN size_NN from_IN 16_CD to_TO 12_CD
        modestly_RB increased_VBD the_DT minimum_JJ detectable_JJ fold-change_JJ from_IN
        3_CD ._. 0_CD to_TO 3_CD ._. 8_CD ._. At_IN a_DT total_JJ sample_NN size_NN lower_JJR than_IN 10_CD ,_, the_DT
        minimum_JJ detectable_JJ fold-change_JJ exceeded_VBD the_DT maximum_NN change_NN
        in_IN expression_NN induced_VBN by_IN mefloquine_NN ._.
      
      
        Discussion_NNP
        The_DT detection_NN of_IN differentially_RB expressed_VBD genes_NNS depends_VBZ
        critically_RB on_IN having_VBG adequate_JJ replication_NN (_( sample_NN size_NN )_) and_CC
        on_IN the_DT selection_NN of_IN appropriate_JJ filtering_VBG methods_NNS (_( in_IN the_DT
        case_NN of_IN this_DT study_NN a_DT 
        P_NN -_: value_NN filtering_VBG method_NN )_) ._. In_IN terms_NNS
        of_IN their_PRP$ ability_NN to_TO detect_VB genes_NNS differentially_RB modulated_JJ
        by_IN mefloquine_NN ,_, the_DT different_JJ 
        P_NN -_: value_NN filtering_VBG methods_NNS can_MD be_VB
        ranked_VBN in_IN terms_NNS of_IN their_PRP$ conservativeness_NNS as_IN follows_VBZ :_:
        Holm-_NNP Bonferroni_NNP >_NN reverse_NN Holm_NNP (_( initial_JJ 
        P_NN <_NN 0_CD ._. 01_CD )_) >_NN reverse_NN Holm_NNP
        (_( initial_JJ 
        P_NN <_NN 0_CD ._. 05_CD )_) >_NN no_DT correction_NN (_( i_NNP ._. e_SYM ._.
        
        P_NN <_NN 0_CD ._. 05_CD )_) ._. These_DT results_NNS are_VBP not_RB
        surprising_JJ if_IN one_CD considers_VBZ the_DT distribution_NN of_IN observed_VBD
        (_( unadjusted_JJ )_) microarray_NN 
        P_NN values_NNS and_CC that_WDT expected_VBD (_( uniform_NN
        if_IN independent_JJ tests_NNS )_) under_IN the_DT complete_JJ null_NN hypothesis_NNS
        that_IN all_DT genes_NNS are_VBP unaltered_JJ (_( Figure_NN 5_LS )_) ._. Application_NNP of_IN the_DT
        reverse_NN Holm_NNP procedures_NNS generates_VBZ relatively_RB few_JJ false_JJ
        positive_JJ results_NNS compared_VBN to_TO no_DT 
        P_NN -_: value_NN correction_NN ,_, but_CC detects_NNS
        genes_NNS more_RBR efficiently_RB than_IN if_IN the_DT Holm-_NNP Bonferroni_NNP
        procedure_NN is_VBZ applied_VBN ._.
        This_DT ,_, of_IN course_NN ,_, begs_VBZ the_DT question_NN as_IN to_TO whether_IN it_PRP is_VBZ
        appropriate_JJ to_TO now_RB conclude_VB that_IN the_DT reverse_NN Holm_NNP procedure_NN
        is_VBZ the_DT most_RBS appropriate_JJ 
        P_NN -_: value_NN filtering_VBG method_NN ._. The_DT
        answer_NN ,_, of_IN course_NN ,_, depends_VBZ on_IN the_DT goal_NN of_IN the_DT proposed_VBN
        study_NN ._. If_IN ,_, for_IN example_NN ,_, one_CD wished_VBD to_TO be_VB certain_JJ that_IN a_DT
        gene_NN is_VBZ differentially_RB expressed_VBN ,_, or_CC does_VBZ not_RB wish_VB to_TO
        resort_VB to_TO laborious_JJ conventional_JJ techniques_NNS to_TO confirm_VB
        expression_NN changes_NNS ,_, the_DT only_RB appropriate_JJ filtering_VBG method_NN
        is_VBZ the_DT Bonferroni_NNP (_( or_CC other_JJ related_VBN )_) procedure_NN ,_, as_IN the_DT
        chance_NN of_IN generating_NN false_JJ positive_JJ results_NNS using_VBG such_JJ
        methods_NNS is_VBZ negligible_JJ ._. However_RB ,_, if_IN one_CD wishes_VBZ to_TO identify_VB
        all_DT differentially_RB expressed_VBN genes_NNS ,_, and_CC possesses_VBZ the_DT
        resources_NNS necessary_JJ to_TO confirm_VB all_DT expression_NN changes_NNS using_VBG
        traditional_JJ approaches_NNS ,_, the_DT 
        P_NN <_NN 0_CD ._. 05_CD threshold_NN (_( or_CC a_DT
        fold-change_JJ method_NN )_) might_MD be_VB the_DT most_RBS appropriate_JJ ._. However_RB
        for_IN many_JJ studies_NNS that_WDT do_VBP not_RB fall_VB at_IN either_DT of_IN these_DT
        extremes_NNS ,_, application_NN of_IN a_DT reverse_NN Holm_NNP procedure_NN might_MD be_VB
        the_DT most_RBS appropriate_JJ choice_NN ._.
        The_DT choice_NN of_IN an_DT appropriate_JJ sample_NN size_NN is_VBZ also_RB
        critical_JJ if_IN (_( true_JJ )_) differentially_RB expressed_VBD genes_NNS are_VBP to_TO
        have_VB a_DT high_JJ probability_NN of_IN being_VBG detected_VBN ._. A_DT power_NN analysis_NN
        was_VBD conducted_VBN to_TO determine_VB whether_IN the_DT transcriptional_NN
        changes_NNS induced_VBN by_IN mefloquine_NN might_MD have_VB been_VBN detectable_JJ
        using_VBG lower_JJR sample_NN sizes_NNS ._. There_EX was_VBD a_DT modest_JJ increase_NN in_IN
        the_DT minimum_JJ detectable_JJ fold-change_JJ of_IN an_DT average_JJ gene_NN when_WRB
        the_DT sample_NN size_NN was_VBD reduced_VBN to_TO twelve_CD from_IN sixteen_NN ._. In_IN
        theory_NN ,_, then_RB ,_, a_DT modest_JJ reduction_NN in_IN sample_NN size_NN may_MD still_RB
        have_VB allowed_VBN many_JJ significant_JJ genes_NNS to_TO be_VB detected_VBN ._. However_RB
        at_IN sample_NN sizes_NNS below_IN ten_CD ,_, the_DT minimum_JJ detectable_JJ
        fold-change_JJ exceeded_VBD the_DT maximum_NN transcriptional_NN modulation_NN
        of_IN any_DT gene_NN by_IN mefloquine_NN ,_, implying_VBG that_IN such_JJ changes_NNS would_MD
        be_VB extremely_RB difficult_JJ if_IN not_RB impossible_JJ to_TO detect_VB ._. These_DT
        observations_NNS may_MD be_VB directly_RB relevant_JJ for_IN planning_VBG future_JJ
        studies_NNS in_IN which_WDT transcriptional_NN changes_NNS of_IN similar_JJ
        magnitude_NN ,_, and_CC data-sets_JJ with_IN similar_JJ variance_NN
        characteristics_NNS ,_, are_VBP expected_VBN ._. However_RB ,_, such_JJ a_DT power_NN
        analysis_NN might_MD be_VB considered_VBN conservative_JJ for_IN studies_NNS in_IN
        which_WDT larger_JJR magnitude_NN fold-changes_JJ are_VBP expected_VBN ._.
        Appropriate_NNP experimental_JJ design_NN is_VBZ also_RB necessary_JJ to_TO
        ensure_VB that_IN any_DT changes_NNS in_IN gene_NN expression_NN observed_VBD are_VBP
        relevant_JJ to_TO the_DT problem_NN being_VBG investigated_VBN ._. The_DT choice_NN of_IN
        cell_NN system_NN ,_, toxicant_NN concentration_NN and_CC exposure_NN time_NN must_MD
        all_DT be_VBP carefully_RB considered_VBN ._. In_IN the_DT present_JJ study_NN ,_, an_DT
        immortal_NN (_( NG_NNP 108_CD )_) cell_NN line_NN was_VBD selected_VBN as_IN these_DT cells_NNS are_VBP
        easier_JJR to_TO maintain_VB 
        in_IN vitro_NN and_CC large_JJ amounts_NNS of_IN RNA_NNP can_MD
        be_VB routinely_RB isolated_VBN ._. Cell_NNP lines_NNS do_VBP not_RB always_RB respond_VB in_IN
        the_DT same_JJ manner_NN that_IN untransformed_JJ cells_NNS would_MD in_IN an_DT 
        in_IN vivo_NN context_NN ;_: therefore_RB their_PRP$ use_NN
        in_IN experimental_JJ model_NN systems_NNS may_MD not_RB always_RB be_VB
        appropriate_JJ ._. However_RB ,_, this_DT does_VBZ not_RB appear_VB to_TO be_VB the_DT case_NN
        for_IN mefloquine_NN ,_, since_IN NG_NNP 108_CD cells_NNS and_CC primary_JJ embryonic_JJ rat_NN
        neurons_NNS appear_VBP similarly_RB susceptible_JJ to_TO the_DT drug_NN (_( Figure_NN
        1_LS )_) ._. The_DT mefloquine_NN concentration_NN (_( 10_CD μM_NN )_) was_VBD selected_VBN on_IN
        the_DT basis_NN of_IN its_PRP$ physiological_JJ relevance_NN [_NN 18_CD 19_CD 20_CD ]_NN and_CC
        ability_NN to_TO elicit_NN a_DT measurable_JJ physiological_JJ response_NN
        without_IN inducing_VBG maximum_NN cell_NN death_NN (_( Figure_NN 1_LS )_) ._. A_DT short_JJ
        exposure_NN time_NN (_( 2_CD h_NN )_) was_VBD selected_VBN for_IN two_CD reasons_NNS ._. Firstly_NNP ,_,
        shorter_JJR toxicant_NN exposure_NN time_NN ensured_JJ that_IN any_DT changes_NNS
        observed_VBD in_IN specific_JJ mRNA_NN transcript_NN levels_NNS were_VBD due_JJ to_TO the_DT
        direct_JJ cellular_JJ effects_NNS of_IN mefloquine_NN ,_, rather_RB than_IN
        secondary_JJ effects_NNS caused_VBN by_IN changing_VBG culture_NN conditions_NNS
        (_( since_IN drug-treated_JJ NG_NNP 108_CD cells_NNS divide_VBP less_RBR rapidly_RB than_IN
        DMSO-treated_NNP cells_NNS )_) ._. Secondly_RB ,_, a_DT short_JJ 
        in_IN vitro_NN exposure_NN time_NN is_VBZ appropriate_JJ
        since_IN the_DT adverse_JJ neurological_JJ effects_NNS of_IN mefloquine_NN 
        in_IN vivo_NN occur_VB within_IN 24_CD -_: 48_CD hours_NNS of_IN
        the_DT first_JJ 1_CD -_: 2_CD doses_NNS administered_VBN [_NN 21_CD 22_CD ]_NN ._.
        Mefloquine_NNP induced_VBD changes_NNS in_IN the_DT expression_NN of_IN three_CD
        genes_NNS ,_, GADD_NNP 153_CD ,_, IkB_NNP and_CC cJun_NN ._. CJun_NNP is_VBZ a_DT transcription_NN
        factor_NN upregulated_JJ in_IN response_NN to_TO many_JJ forms_NNS of_IN
        neurological_JJ injury_NN [_NN 23_CD ]_NN ,_, thus_RB its_PRP$ modulation_NN by_IN
        mefloquine_NN under_IN conditions_NNS of_IN cellular_JJ stress_NN is_VBZ
        unsurprising_JJ and_CC does_VBZ not_RB imply_VB a_DT specific_JJ mechanism_NN of_IN
        action_NN ._. However_RB ,_, this_DT is_VBZ not_RB the_DT case_NN for_IN GADD_NNP 153_CD and_CC IkB_NNP ._.
        Two_CD highly_RB conserved_JJ responses_NNS are_VBP observed_VBN under_IN
        conditions_NNS of_IN endoplasmic_JJ reticulum_NN (_( ER_NNP )_) stress_NN ;_: the_DT ER_NNP
        overload_NN and_CC unfolded_VBD protein_NN responses_NNS [_NN 24_CD 25_CD ]_NN ._. The_DT
        unfolded_VBD protein_NN response_NN is_VBZ characterized_VBN by_IN generalized_JJ
        suppression_NN of_IN protein_NN synthesis_NN and_CC the_DT specific_JJ induction_NN
        of_IN ER-resident_NNP proteins_NNS and_CC GADD_NNP 153_CD [_NN 24_CD ]_NN ._. The_DT
        transcription_NN factor_NN nuclear_JJ factor_NN kB_NN is_VBZ activated_VBN during_IN
        the_DT ER_NNP overload_NN response_NN ,_, leading_VBG to_TO the_DT downstream_JJ
        induction_NN of_IN pro-inflammatory_JJ proteins_NNS [_NN 25_CD ]_NN ._. Therefore_RB ,_,
        the_DT transcriptional_NN modulation_NN of_IN GADD_NNP 153_CD and_CC IkB_NNP by_IN
        mefloquine_NN suggests_VBZ that_IN the_DT ER_NNP might_MD be_VB a_DT target_NN of_IN the_DT
        drug_NN ._.
        In_IN neurons_NNS ,_, GADD_NNP 153_CD is_VBZ selectively_RB upregulated_JJ under_IN
        conditions_NNS of_IN endoplasmic_JJ reticulum_NN (_( ER_NNP )_) stress_NN arising_VBG
        from_IN depletion_NN of_IN calcium_NN stores_NNS [_NN 26_CD ]_NN ._. Here_RB ,_, the_DT
        upregulation_NN of_IN GADD_NNP 153_CD was_VBD observed_VBN after_IN mefloquine_NN
        treatment_NN in_IN NG_NNP 108_CD cells_NNS (_( 10_CD μM_NN for_IN 2_CD h_NN )_) ._. In_IN preliminary_JJ
        experiments_NNS utilizing_VBG primary_JJ rat_NN neurons_NNS ,_, we_PRP have_VBP also_RB
        observed_VBN an_DT upregulation_NN of_IN GADD_NNP 153_CD after_IN mefloquine_NN
        treatment_NN (_( unpublished_JJ data_NNS )_) ._. Mefloquine_NNP has_VBZ been_VBN found_VBN to_TO
        alter_VB calcium_NN flux_NN ,_, into_IN and_CC out_IN of_IN ,_, isolated_VBN skeletal_NN
        muscle_NN and_CC brain_NN microsomes_NNS ,_, via_IN an_DT inhibitory_NN effect_NN of_IN
        the_DT compound_NN on_IN the_DT ER_NNP calcium_NN pump_NN and_CC calcium_NN release_NN
        channels_NNS (_( IC_NNP 
        50_CD of_IN 42_CD -_: 43_CD uM_NN ,_, [_NN 27_CD 28_CD ]_NN )_) ._. Plasma_NNP
        mefloquine_NN concentrations_NNS (_( therapeutic_JJ dosing_VBG )_) may_MD reach_VB 21_CD
        μM_NN [_NN 18_CD ]_NN and_CC the_DT drug_NN crosses_VBZ the_DT blood-brain_JJ barrier_NN ,_,
        accumulating_VBG to_TO concentrations_NNS in_IN excess_NN of_IN 50_CD and_CC 90_CD μM_NN in_IN
        the_DT brains_NNS of_IN humans_NNS and_CC rats_NNS respectively_RB [_NN 19_CD 20_CD ]_NN ._.
        Therefore_RB ,_, these_DT biochemical_JJ effects_NNS occur_VBP at_IN
        concentrations_NNS within_IN a_DT relevant_JJ physiological_JJ range_NN ._.
        Collectively_RB ,_, these_DT observations_NNS suggest_VBP that_IN mefloquine_NN
        disrupts_NNS neuronal_NN function_NN through_IN a_DT combination_NN of_IN
        disrupted_VBN calcium_NN homeostasis_NNS and_CC ER_NNP stress_NN ._. This_DT
        hypothesis_NNS is_VBZ currently_RB under_IN investigation_NN in_IN this_DT
        laboratory_NN ._.
      
      
        Conclusions_NNP
        Adequate_NNP sample_NN sizes_NNS and_CC appropriate_JJ selection_NN of_IN 
        P_NN -_: value_NN filtering_VBG methods_NNS are_VBP
        essential_JJ for_IN the_DT efficient_JJ and_CC effective_JJ detection_NN of_IN
        differentially_RB expressed_VBD genes_NNS ._. Mefloquine_NNP induced_VBD changes_NNS
        in_IN the_DT expression_NN of_IN genes_NNS encoding_VBG cJun_NN ,_, IkB_NNP and_CC the_DT ER_NNP
        stress_NN response_NN protein_NN GADD_NNP 153_CD ._. The_DT upregulation_NN of_IN
        GADD_NNP 153_CD by_IN mefloquine_NN suggests_VBZ that_IN the_DT drug_NN might_MD affect_VB
        the_DT function_NN of_IN the_DT ER_NNP in_IN neurons_NNS ,_, perhaps_RB by_IN disruption_NN of_IN
        calcium_NN homeostasis_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
